Multiple Myeloma
Key Points
Key Points
The estimated number of deaths from multiple myeloma in 2018 is 12,770, representing 2.1% of all cancer deaths.
Despite significant advances and improvements in overall survival, multiple myeloma remains incurable and additional treatments are needed.
The median survival is just over 5 years and most patients receive 4 or more different lines of therapy throughout their disease course.
Treatment
...reatme...
...ransplant Eligible
...should be referred to a transplant center to...
...and renal function should not be the sole c...
...imen and number of cycles remain unproven. Ho...
...ant should be offered to all transplant-...
...nts associated with stem cell toxicity,...
...cell collection (sufficient for more...
...of minimal response required to proceed t...
...elphalan is the recommended conditioning...
...logous SCT should not be routinely r...
...e or delayed SCT may be used as co...
...ogeneic transplant for multiple myeloma...
...therapy is not routinely recommende...
...lidomide maintenance therapy should be...
...tolerant of or unable to receive lenalidomide,...
For high-risk patients, maintenanc...
...nsufficient evidence to make modif...
...uality and depth of response should be asses...
...al of initial therapy for transplant eligible...
...d that depth of response be assessed with...
...hole-body low dose CT scan has been shown to be...
...ransplant Ineligible...
...reatment recommendations for patien...
...tment for patients with multiple myeloma who are t...
...s for patients with multiple myeloma who are...
...ysicians/patients should balance the potential imp...
...inuous therapy should be offered over fixe...
...l of initial therapy for transplant ineligible...
...f response for all patients should be ass...
There is insufficient evidence to suppor...
...ation of therapy, one should defin...
...recommended that patients be monitored closely...
...sed Disease...
...nt for biochemically relapsed myeloma should be in...
All clinically relapsed patients with sy...
Triplet therapy should be administered on first...
...f relapsed multiple myeloma may be...
...pies should be taken into consideration when sele...
...cell transplantation, if not received after prima...
...isk status of the patients should be as...
...k assessment at the time of relapse sh...
...essment of other risk factors such as r...
...patients with genetic high-risk diseas...
...ts with renal insufficiency, drugs should be...
...atients with plasma cell leukemia o...
...evised response criteria should be used for r...
...asurable parameters need to be followed includi...
...cluding marrow and imaging should be...
...assessment should be performed after one cycle...
...Algorithm On Management of Patients with Multipl...
...le 1. Drugs Used in the Management of Patient...
...stic Criteria for Active Multiple MyelomaHav...
...ble 3. Revised International Staging System (R-...
...Comparison of Select Risk Prediction Models...
...e 5. IMWG Response CriteriaHaving trouble view...
...ted Cost of Drugs for Multiple Mye...